Liang Li - Talis Biomedical CoFounder Strategy
Insider
Liang Li is CoFounder Strategy of Talis Biomedical Corp
| Phone | 650 433 3000 |
| Web | https://talisbio.com |
Talis Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.2959) % which means that it has lost $0.2959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7048) %, meaning that it created substantial loss on money invested by shareholders. Talis Biomedical's management efficiency ratios could be used to measure how well Talis Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Talis Biomedical Corp currently holds 19.67 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Talis Biomedical Corp has a current ratio of 12.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Talis Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Talis Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Talis Biomedical Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Talis to invest in growth at high rates of return. When we think about Talis Biomedical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Veronica Cai | Tivic Health Systems | 48 | |
| Reay Brown | Sight Sciences | N/A | |
| Sam Park | Sight Sciences | 63 | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Sandra Eayrs | Nuwellis | N/A | |
| MBA BS | Sight Sciences | N/A | |
| Rob Scott | Nuwellis | N/A | |
| Alessandraa Pavesio | Bioventus | 57 | |
| Kenneth CPA | Bluejay Diagnostics | 44 | |
| John Ordway | Sight Sciences | N/A | |
| Richard Ginn | Tenon Medical | 58 | |
| Jason Cook | Bluejay Diagnostics | 42 | |
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Rebecca Kuhn | Neuropace | 63 | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Jeff Welch | Bioventus | N/A | |
| Mark Saxton | Neuropace | 59 | |
| Katrina Church | Bioventus | 62 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Stacie Rodgers | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 |
Talis Biomedical Corp Leadership Team
Elected by the shareholders, the Talis Biomedical's board of directors comprises two types of representatives: Talis Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talis. The board's role is to monitor Talis Biomedical's management team and ensure that shareholders' interests are well served. Talis Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talis Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Moody, Chief Officer | ||
| Gillian Green, Company Secretary | ||
| Margaret MS, Controller | ||
| Rustem Ismagilov, CoFounder Director | ||
| Rebecca Markovich, Interim Officer | ||
| Jill Green, Senior Legal | ||
| Andrew Lukowiak, President Officer | ||
| MBA Moody, Chief Officer | ||
| Robert MBA, CEO Director | ||
| Liang Li, CoFounder Strategy | ||
| Emily Faucette, Senior Relations | ||
| Matthew Pepe, Director Resource |
Talis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Talis Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 52.15 % | ||||
| Number Of Shares Shorted | 17.96 K | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world |